Can you stop gout medicine if ultrasound is clear?
Part of Bones, joints & muscles, Kidney & urinary clinical trials.
This trial tests whether people with well-controlled gout can safely stop their urate-lowering medication (allopurinol or febuxostat) if an ultrasound shows no urate crystals in their joints. It may help you avoid unnecessary medication while keeping your gout under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have gout diagnosed by a doctor.
- You have not had a gout flare for at least 2 years.
- You have no tophi (urate lumps under the skin).
- You take allopurinol or febuxostat for at least 2 years and your uric acid level is 60 mg/L or less.
- An ultrasound shows no urate crystals in your big toe or knee joints.
- You are willing to keep using effective birth control if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if gradually lowering the dose of the gout medication febuxostat is safe for people whose gout has been well-controlled for at least 5 years. The goal is to see if a lower dose can still keep uric acid levels in a healthy range.
This study compares two different treatment goals for a blood level called urate in people with gout. The goal is to see which approach lowers gout flares better while helping people feel better.
This trial checks if testing for a specific gene (HLA-B*58:01) before starting gout medication can prevent severe allergic reactions. It compares standard care with a gene-guided approach to see which is safer and works better.
This trial tests a new medicine called tigulixostat against febuxostat, a standard gout treatment, to see which works better at lowering uric acid levels. You may qualify if you have gout with high uric acid and have not had a gout flare in the last month.
This trial tests an experimental tablet (SHR4640) added to the standard gout medicine febuxostat (40 mg daily) for people whose uric acid remains too high despite febuxostat alone. The goal is to see if the combination lowers uric acid more effectively and safely.
This trial tests a new tablet (HR091506) for adults with gout and high uric acid. It aims to lower uric acid levels and reduce gout attacks, especially for people with more severe gout (like tophi or frequent attacks).
Hear when a new Gout Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.